Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Siltuximab by Recordati for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Siltuximab is under clinical development by Recordati and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...
Data Insights
Siltuximab by Recordati for Pain: Likelihood of Approval
Siltuximab is under clinical development by Recordati and currently in Phase II for Pain. According to GlobalData, Phase II drugs...